What BMI Qualifies for Wegovy? A Guide to Eligibility and Weight Management Options

Last reviewed: July 8, 2026

Last updated: July 8, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Wegovy (semaglutide) eligibility is based on BMI thresholds set by the FDA, but access and affordability vary significantly across different treatment providers. A BMI of 30 or higher, or 27 with weight-related health conditions, traditionally qualifies patients for semaglutide therapy. PlexusDx provides compounded semaglutide injections through licensed 503A pharmacies, offering accessible alternatives to branded options for qualifying patients nationwide.

Understanding BMI Eligibility Thresholds for Semaglutide

BMI (Body Mass Index) serves as the primary screening tool for semaglutide prescription eligibility. The standard threshold is a BMI of 30 kg/m² or higher, which falls into the obesity classification. However, patients with a BMI between 27 and 29.9 who have at least one weight-related condition—such as type 2 diabetes, hypertension, or sleep apnea—also qualify for treatment. Your BMI is calculated by dividing your weight in kilograms by your height in meters squared, providing a quick assessment tool that healthcare providers use to determine candidacy.

Weight-related comorbidities expand access beyond strict BMI cutoffs. Conditions like cardiovascular disease, non-alcoholic fatty liver disease, and chronic kidney disease all strengthen the clinical case for semaglutide therapy even at lower BMI ranges. Many patients discover they qualify once their complete health picture is evaluated by a qualified provider. PlexusDx connects patients with licensed prescribers who assess the full clinical context, not just BMI numbers alone.

How Compounded Semaglutide Differs from Branded Wegovy

Wegovy is FDA-approved semaglutide manufactured by Novo Nordisk, whereas PlexusDx sources compounded semaglutide from licensed 503A compounding pharmacies that prepare the medication in compliance with strict pharmaceutical standards. Both contain the same active ingredient—semaglutide—but compounded versions offer significant cost savings and eliminates insurance barriers. Compounded semaglutide injections through PlexusDx are $189/mo month-to-month, or from $149/mo on the 6-month plan, compared to Wegovy's typical retail pricing that often exceeds $900 monthly without insurance coverage.

Quality and safety standards remain consistent across licensed 503A compounding pharmacies, which operate under FDA oversight and state board regulation. These pharmacies compound semaglutide to the same pharmaceutical specifications as branded versions, ensuring potency and sterility. The primary difference is manufacturing scale and branding rather than therapeutic efficacy, making compounded options a clinically sound choice for patients seeking affordability without compromising quality.

Medical Conditions That Expand Your Semaglutide Eligibility

Beyond BMI requirements, semaglutide eligibility broadens significantly when patients have established metabolic or cardiovascular conditions. Type 2 diabetes mellitus substantially increases eligibility, as semaglutide was originally developed as a diabetes medication and demonstrates cardiovascular benefits in this population. Hypertension, dyslipidemia, and obstructive sleep apnea all serve as weight-related comorbidities that make patients candidates for therapy even at lower BMI thresholds. Your prescriber evaluates these conditions holistically to determine whether semaglutide aligns with your overall health management strategy.

Inflammatory markers, insulin resistance patterns, and family history of metabolic disease further inform eligibility assessment. Some patients discover through advanced testing that their weight challenges stem from genetic susceptibility to appetite regulation or metabolic dysfunction. The PlexusDx Precision Peptide Genetic Test identifies variants in genes like GLP1R rs6923761 and MC4R rs17782313 that influence how your body responds to GLP-1 therapy, enabling truly personalized treatment selection based on your genetic pathway.

Accessing Compounded Semaglutide Without Insurance Barriers

Insurance coverage for semaglutide remains inconsistent and often requires prior authorization, lengthy appeals processes, or documented weight-loss failure on other medications first. PlexusDx eliminates these barriers by offering compounded semaglutide injections at flat monthly rates without requiring insurance verification or membership fees. Your dose may increase as your body adapts to therapy, but your price won't—semaglutide injections remain $189 per month across all three commitment tiers, providing transparent, predictable costs from start to finish.

HSA and FSA accounts are accepted at PlexusDx, making compounded semaglutide accessible through pre-tax health savings accounts for eligible patients. All 50 states receive service, and treatment begins with a telehealth consultation to confirm eligibility and establish baseline health metrics. This accessibility model removes geographic, insurance, and financial obstacles that traditionally prevented qualified patients from accessing proven weight loss therapy.

Choosing Between Injectable and Oral Semaglutide Options

PlexusDx offers both compounded semaglutide injections ($189/month) and oral semaglutide tablets ($289/month), allowing patients to select based on preference, convenience, and lifestyle factors. Injectable semaglutide typically demonstrates more predictable absorption and higher bioavailability, as it bypasses first-pass hepatic metabolism and enters circulation directly. Oral formulations offer convenience for needle-averse patients but require specific administration protocols—taken on an empty stomach without food or drink for 30 minutes—to optimize absorption rates.

Clinical trials show comparable weight loss outcomes between injectable and oral semaglutide when dosed appropriately and protocols are followed correctly. Injectable therapy may reach higher peak concentrations with lower overall doses, while oral therapy requires higher doses to achieve similar systemic exposure. Your choice should align with your comfort level, daily routine, and prescription adherence patterns—both modalities are supported by robust clinical evidence when used correctly.

The Role of Genetic Testing in Semaglutide Response Prediction

The PlexusDx Precision Peptide Genetic Test analyzes GLP1R (rs6923761), and GIPR (rs1800437) — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to semaglutide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

This genetic data, available as a $99 add-on test after your first month of treatment, enables truly personalized therapy optimization. Understanding your genetic predispositions helps your prescriber adjust dosing strategies, select between semaglutide and tirzepatide, or combine compounds for enhanced results. Patients with certain genetic variants may benefit from the PlexusDx GLP-Squared dual-compound approach, at $289/mo month-to-month, or from $249/mo on the 3-month plan, which targets multiple appetite-regulation pathways simultaneously for synergistic weight loss benefits.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What is the minimum BMI to qualify for semaglutide therapy?

The standard minimum BMI is 30 kg/m² for semaglutide eligibility. However, patients with a BMI between 27 and 29.9 who have weight-related conditions like diabetes, hypertension, or sleep apnea also qualify. PlexusDx prescribers evaluate your complete health picture during telehealth consultation to confirm eligibility based on clinical guidelines.

How much weight can I expect to lose with semaglutide?

No — the Precision Peptide Genetic Test does not predict your response to semaglutide or any specific medication. It analyzes pathway-level variants (GLP1R, GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Is PlexusDx compounded semaglutide safe and effective?

PlexusDx sources compounded semaglutide exclusively from licensed 503A compounding pharmacies operating under FDA oversight and state board regulation. These facilities prepare semaglutide to identical pharmaceutical specifications as branded versions, ensuring potency, sterility, and efficacy while offering significant cost savings.

What are common side effects of semaglutide injections?

Gastrointestinal effects like nausea, vomiting, diarrhea, and constipation occur in 20-50% of patients during dose escalation, typically resolving within 2-4 weeks as your body adjusts. Rare but serious risks include pancreatitis and gallbladder complications. Your PlexusDx prescriber monitors for adverse effects and can adjust dosing if side effects are severe.

Can genetic testing improve my semaglutide results?

No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (GLP1R, GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Related Reading

• Weight Management Peptide Pathway Guide
• Wegovy For Losing Weight
• Wegovy Bmi
• Wegovy For Weight Loss 2

Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.